Paid-in Capital Increase Schedule Postponed
경남제약
053950
Signal Score
Historical Avg Return (5d)
+0.33%
Data Coverage
100%n=2377
Risk-adjusted indicator based on 2377 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Original Final Issue Price Determination Date: July 29, 2026
- • Original Subscription Period for Existing Shareholders: August 3-4, 2026
- • Original General Public Offering Period: August 6-7, 2026
- • Discount Rate for New Share Price Calculation: 25%
- • Maximum Discount Rate for Final Issue Price: 40%
AI Analysis Summary
KYUNG NAM PHARM.CO.,LTD. announced an amendment to its paid-in capital increase plan. The original schedule for the new share issue price determination (July 29, 2026), existing shareholder subscription (August 3-4, 2026), and general public offering (August 6-7, 2026) has been postponed to 'to be determined later' due to a request from the Financial Supervisory Service for an amendment to the securities registration statement. The new share price will be calculated using a 25% discount rate from the reference price, with a maximum 40% discount from the weighted average stock price over 3-5 trading days prior to the subscription date. This delay introduces uncertainty and potential for further changes, which is a negative for investors.
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.